News
Analysts' ratings for Ionis Pharmaceuticals IONS over the last quarter vary from bullish to bearish, as provided by 10 ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $65 and keeps a Buy rating on the shares following FDA ...
Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...
Good morning. The Supreme Court is allowing the Trump administration to cut $783 million in research grants tied to DEI work.
TipRanks on MSN4h
Ionis Pharmaceuticals price target raised to $69 from $65 at Citi
Citi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $65 and keeps a Buy rating on the shares following the FDA ...
Major developments in health include the U.S. Supreme Court's decision to allow cuts to NIH grants under Trump, the famine ...
Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback